The GORE TAG conformable thoracic stent graft with the new ACTIVE CONTROL deployment system.
Aged
Aorta, Thoracic
/ diagnostic imaging
Aortic Diseases
/ diagnostic imaging
Blood Vessel Prosthesis
Blood Vessel Prosthesis Implantation
/ adverse effects
Endovascular Procedures
/ adverse effects
Female
Humans
Male
Middle Aged
Postoperative Complications
/ mortality
Prosthesis Design
Retrospective Studies
Risk Factors
Stents
Time Factors
Treatment Outcome
ACTIVE CONTROL
C-TAG
Conformability
TEVAR
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
18
07
2018
accepted:
05
11
2018
pubmed:
30
3
2019
medline:
28
1
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
The aim of this study was to describe single-center intraoperative details and early outcome of the new GORE TAG conformable stent graft with ACTIVE CONTROL (C-TAG ACTIVE CONTROL; W. L. Gore & Associates, Flagstaff, Ariz). Between September 2017 and June 2018, a consecutive 30 patients underwent thoracic endovascular aortic repair with C-TAG ACTIVE CONTROL. This new system provides an intermediate deployment step at 50% and optional angulation control of the proximal part of the stent graft. Indications for thoracic endovascular aortic repair varied widely, including chronic postdissection and degenerative aneurysms, complicated acute dissections, and intramural hematomas, among others, in an elective (63.3%), urgent (13.3%), or emergent (23.3%) setting. The proximal landing zone (LZ) was LZ 2 in 23.3%, LZ 3 in 43.3%, and LZ 4 in 33.3%. Data were collected retrospectively and analyzed for technical and clinical success. In all patients, the stent graft was successfully introduced and deployed at the intended position, with complete exclusion of aortic disease and without intraoperative mortality (primary technical success, 100%). One emergent patient died at 2 days of ongoing septic shock (clinical success at 30 days, 96.6%). Median follow-up was 107 days (range, 33-271 days); late mortality was 3.4% (one patient died of stent graft infection at 40 days). Freedom from type I and type III endoleak at the early follow-up was 100%. No patients required other surgical or endovascular procedures for the primary treated aortic disease. Our reported initial experience in 30 patients with the C-TAG ACTIVE CONTROL showed excellent early results, with high deployment accuracy and conformability. The additional features of staged deployment and angulation control may be of great help in challenging aortic arch diseases, allowing precise positioning and preventing bird-beak effect.
Identifiants
pubmed: 30922741
pii: S0741-5214(18)32648-X
doi: 10.1016/j.jvs.2018.11.015
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-437Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.